MedTrace Logo

The Effect of Rifapentine on Raltegravir

NCT00809718 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2015-10-22

No results posted yet for this study

Summary

The aim of this study is to study the effect of rifapentine on plasma concentrations of raltegravir.

Conditions

  • Healthy

Interventions

DRUG

Raltegravir and rifapentine

Period 1- Raltegravir 400 mg q12h by mouth for 4 days Period 2- Rifapentine 900 mg taken by mouth once per week for 3 doses and raltegravir 400 mg q12h by mouth for 4 days Period 3- Rifapentine 600 mg taken by mouth once daily for 5 of 7 days per week for 10 doses and raltegravir 400 mg q12h by mouth for 4 days

Sponsors & Collaborators

Principal Investigators

  • Marc Weiner, M.D. · The University of Texas Health Science Center at San Antonio

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2011-05-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00809718 on ClinicalTrials.gov